Difference between revisions of "Merkel cell carcinoma"
Jump to navigation
Jump to search
| Line 34: | Line 34: | ||
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]] | !style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]] | ||
|- | |- | ||
| − | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4927341/ Nghiem et al. 2016 ( | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4927341/ Nghiem et al. 2016 (KEYNOTE-017)] |
| − | |style="background-color:#91cf61"|Phase II | + | |style="background-color:#91cf61"|Phase II (RT) |
|56% (95% CI 35-76%) | |56% (95% CI 35-76%) | ||
|- | |- | ||
| Line 45: | Line 45: | ||
===References=== | ===References=== | ||
| − | # ''' | + | # '''KEYNOTE-017:''' Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, Berry S, Chartash EK, Daud A, Fling SP, Friedlander PA, Kluger HM, Kohrt HE, Lundgren L, Margolin K, Mitchell A, Olencki T, Pardoll DM, Reddy SA, Shantha EM, Sharfman WH, Sharon E, Shemanski LR, Shinohara MM, Sunshine JC, Taube JM, Thompson JA, Townson SM, Yearley JH, Topalian SL, Cheever MA. PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma. N Engl J Med. 2016 Jun 30;374(26):2542-52. Epub 2016 Apr 19. [https://www.nejm.org/doi/full/10.1056/NEJMoa1603702 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4927341/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27093365 PubMed] |
[[Category:Merkel cell carcinoma regimens]] | [[Category:Merkel cell carcinoma regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
[[Category:Skin cancers]] | [[Category:Skin cancers]] | ||
Revision as of 15:38, 15 September 2019
| Section editor | |
|---|---|
 |
Elizabeth Buchbinder, MD Dana-Farber Cancer Institute Boston, MA |
3 regimens on this page
3 variants on this page
|
Guidelines
NCCN
Metastatic or advanced disease, all lines of therapy
Avelumab monotherapy
Avelumab (Bavencio) for merkel cell carcinoma
Pembrolizumab monotherapy
| back to top |
Regimen
| Study | Evidence | Efficacy |
|---|---|---|
| Nghiem et al. 2016 (KEYNOTE-017) | Phase II (RT) | 56% (95% CI 35-76%) |
Immunotherapy
- Pembrolizumab (Keytruda) 2 mg/kg IV once on day 1
21-day cycle for up to 35 cycles (2 years) or until CR
References
- KEYNOTE-017: Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, Berry S, Chartash EK, Daud A, Fling SP, Friedlander PA, Kluger HM, Kohrt HE, Lundgren L, Margolin K, Mitchell A, Olencki T, Pardoll DM, Reddy SA, Shantha EM, Sharfman WH, Sharon E, Shemanski LR, Shinohara MM, Sunshine JC, Taube JM, Thompson JA, Townson SM, Yearley JH, Topalian SL, Cheever MA. PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma. N Engl J Med. 2016 Jun 30;374(26):2542-52. Epub 2016 Apr 19. link to original article link to PMC article contains verified protocol PubMed